Loading clinical trials...

TERMINATED

Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients

Observational Prospective Study of Survival, Treatment Patterns, Disease and Economic Outcomes in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC) With Progression During or After a First-line Docetaxel-based Regimen

NCT01076751•Sanofi

View on ClinicalTrials.gov

Summary

Primary Objective: * Describe real-life survival of CRPC patients who received first-line docetaxel and have disease progression Secondary Objective: * Describe treatment patterns * Describe the characteristics and outcomes of patients who received second-line taxane-based treatment compared to others * Describe economic and patient-reported outcomes

Eligibility

Age

All ages

Sex

MALE

Healthy Volunteers

No

Inclusion Criteria

•Patients with CRPC progressing during the course of first line docetaxel-based chemotherapy or after at least 3 cycles (equivalent to 225mg/m2) of first line docetaxel-based chemotherapy
•Patient who have given their written consent

Exclusion Criteria

•Current participation in a clinical trial for the second-line treatment of prostate cancer
•Patients having received less than 3 cycles of first line docetaxel-based chemotherapy and discontinued for a reason other than disease progression or toxicity
•Patients having already started a second line treatment
•The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Locations (5)

Sanofi-Aventis Administrative Office

Bridgewater, New Jersey, United States

Sanofi-Aventis Administrative Office

Paris, France

Sanofi-Aventis Administrative Office

Frankfurt, Germany

Sanofi-Aventis Administrative Office

Barcelona, Spain

Sanofi-Aventis Administrative Office

Guildford Surrey, United Kingdom

Key Dates

Start Date

February 1, 2010

Primary Completion Date

October 1, 2010

Completion Date

October 1, 2010

Last Updated

February 14, 2011

Enrollment

82

ACTUAL participants

Conditions

Prostatic Neoplasms

Sponsors

Lead Sponsor

Sanofi

Related Studies

RECRUITINGPHASE3

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT07225946

Prostatic Neoplasms, Castration-Resistant

RECRUITINGPHASE1/PHASE2

64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

NCT04868604

Prostatic Neoplasms, Castration-Resistant

Prostate Active Surveillance Study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 14, 2011Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions